Physician profile
Ann Vo
NPI 1336484468
$2,789.98
in general payments reported to CMS, 2019-2025
25 companies · $784 in 2025
The $784 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $552 · 2022: $566 · 2023: $372 · 2024: $516 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,188 · Education: $484.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.21 |
| Education | $483.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $404.10 | 2021-2025 | Monjuvi |
| Janssen Biotech, INC. | $343.52 | 2021-2024 | Darzalex, Talvey, Tecvayli |
| Karyopharm Therapeutics INC. | $224.73 | 2021-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $191.32 | 2022 | |
| Janssen Scientific Affairs, LLC | $168.89 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Lilly USA, LLC | $168.52 | 2024-2025 | Jaypirca |
| Adc Therapeutics America, INC. | $154.08 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $132.10 | 2021-2023 | |
| Gilead Sciences, INC. | $98.16 | 2025 | Vemlidy |
| Btg International INC. | $93.12 | 2023-2025 | Voraxaze |
| Kite Pharma, INC. | $90.18 | 2021 | |
| Novo Nordisk INC | $90.03 | 2021-2023 | Rybelsus, Ozempic |
| Seagen INC. | $83.00 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $80.59 | 2023-2024 | Calquence |
| Celgene Corporation | $77.74 | 2022-2025 | Pomalyst, Breyanzi |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $76.24 | 2021-2022 | |
| Genzyme Corporation | $61.98 | 2023 | |
| Janssen Pharmaceuticals, INC | $55.26 | 2021-2022 | |
| Amgen INC. | $50.52 | 2022 | |
| Pfizer INC. | $39.80 | 2025 | |
| Legend Biotech USA INC. | $24.78 | 2022 | |
| Morphosys, US INC. | $24.75 | 2021 | |
| Kyowa Kirin, INC. | $23.02 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.50 | 2022 | |
| Abbvie INC. | $16.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.